Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$3.17 +2.6%	$2.41	$1.14 ▼ $7.20	$185.08M	0.68	823,692 shs	688,142 shs
ENOB Enochian Biosciences		$0.61	$0.39 ▼ $2.99	$40.80M	1.09	137,347 shs	88,300 shs
ENTA Enanta Pharmaceuticals	$7.23 +2.6%	$5.97	$4.09 ▼ $17.24	$150.71M	0.76	284,786 shs	98,747 shs
TLSA Tiziana Life Sciences	$1.60 -3.0%	$1.35	$0.63 ▼ $1.91	$192.80M	-0.09	473,953 shs	175,095 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+2.59%	+7.09%	+30.99%	-52.83%	-12.67%
ENOB Enochian Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
ENTA Enanta Pharmaceuticals	+2.55%	-9.06%	+21.31%	+12.27%	-38.88%
TLSA Tiziana Life Sciences	-3.03%	+9.59%	+8.11%	+24.03%	+118.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.7177 of 5 stars	3.5	3.0	0.0	0.0	2.4	1.7	0.6
ENOB Enochian Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	3.6035 of 5 stars	3.4	1.0	0.0	4.7	1.3	2.5	0.0
TLSA Tiziana Life Sciences	1.0177 of 5 stars	0.0	5.0	0.0	0.0	1.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	3.00	Buy	$9.50	199.68% Upside
ENOB Enochian Biosciences	0.00	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$18.00	148.96% Upside
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ENOB, ENTA, ALDX, and TLSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
5/19/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/7/2025	ALDX Aldeyra Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $9.00
4/4/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$1.19 per share	N/A
ENOB Enochian Biosciences	N/A	N/A	N/A	N/A	$1.37 per share	N/A
ENTA Enanta Pharmaceuticals	$67.64M	2.29	N/A	N/A	$6.08 per share	1.19
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.97	N/A	N/A	N/A	N/A	-72.58%	-52.32%	7/30/2025 (Estimated)
ENOB Enochian Biosciences	-$113.43M	N/A	0.00	N/A	N/A	N/A	-154.69%	-130.66%	N/A
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	N/A	-149.57%	-79.83%	-26.65%	8/4/2025 (Estimated)
TLSA Tiziana Life Sciences	-$11.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	6/23/2025 (Estimated)

Latest ENOB, ENTA, ALDX, and TLSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	ALDX Aldeyra Therapeutics	-$0.25	-$0.17	+$0.08	-$0.17	($0.80) million	N/A
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
ENOB Enochian Biosciences	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	0.24	6.49	6.49
ENOB Enochian Biosciences	N/A	0.33	0.33
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
TLSA Tiziana Life Sciences	N/A	1.02	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
ENOB Enochian Biosciences	7.16%
ENTA Enanta Pharmaceuticals	94.99%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	9.60%
ENOB Enochian Biosciences	21.72%
ENTA Enanta Pharmaceuticals	13.89%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	15	59.90 million	54.15 million	Optionable
ENOB Enochian Biosciences	22	58.28 million	45.63 million	Not Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
TLSA Tiziana Life Sciences	8	116.85 million	70.32 million	Optionable

ENOB, ENTA, ALDX, and TLSA Headlines

Recent News About These Companies

Tiziana Life Sciences (NASDAQ:TLSA) Trading 5.8% Higher - Time to Buy?

June 18 at 12:47 AM | marketbeat.com

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

June 13, 2025 | seekingalpha.com

Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing

June 13, 2025 | proactiveinvestors.com

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

June 13, 2025 | globenewswire.com

Tiziana Life Sciences to Present at the Bio International Convention

June 13, 2025 | globenewswire.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% - Still a Buy?

May 28, 2025 | marketbeat.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23, 2025 | finance.yahoo.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23, 2025 | globenewswire.com

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025 | finance.yahoo.com

Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows

May 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences reports purchase of shares by chairman

May 12, 2025 | msn.com

Tiziana Life Sciences Announces Purchase of Shares by Chairman

May 12, 2025 | globenewswire.com

Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab

May 9, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025 | globenewswire.com

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

May 8, 2025 | pmlive.com

Tiziana shares surge 21% on promising multiple sclerosis data

May 6, 2025 | proactiveinvestors.com

Tiziana reports encouraging results for nasal MS drug in early study

May 6, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025 | globenewswire.com

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

April 30, 2025 | insidermonkey.com

Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts

April 23, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

April 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
By Gabriel Osorio-Mazilli | June 6, 2025
View A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly
By Jeffrey Neal Johnson | June 10, 2025
View ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly
Why Analysts Are Bullish on Celsius Stock After 30% Drop
By Gabriel Osorio-Mazilli | June 16, 2025
View Why Analysts Are Bullish on Celsius Stock After 30% Drop
Ignore the Noise—Samsara Stock Is Still a Strong Buy
By Sam Quirke | June 12, 2025
View Ignore the Noise—Samsara Stock Is Still a Strong Buy
Williams-Sonoma: A Fundamentally Good Buy On Sale Now
By Thomas Hughes | May 23, 2025
View Williams-Sonoma: A Fundamentally Good Buy On Sale Now

ENOB, ENTA, ALDX, and TLSA Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$3.17 +0.08 (+2.59%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.16 -0.01 (-0.32%)

As of 06/18/2025 06:57 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Enochian Biosciences NASDAQ:ENOB

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Enanta Pharmaceuticals NASDAQ:ENTA

$7.23 +0.18 (+2.55%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$7.27 +0.04 (+0.61%)

As of 06/18/2025 07:48 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Tiziana Life Sciences NASDAQ:TLSA

$1.60 -0.05 (-3.03%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.66 +0.05 (+3.44%)

As of 06/18/2025 07:26 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time